Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | CCNK | O75909 | 2/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11807077 | 0.91 | LMNA (0.50) | OPRD1CHRM2CHRM3LMNAUSP2 | |
| SCHEMBL28009924 | 0.83 | ALDH1A1 (0.39) | OPRD1CHRM2CHRM3ALDH1A1MAPK1 | |
| SCHEMBL29002632 | 0.81 | CHRM2 (0.48) | OPRD1CHRM2CHRM3LMNAUSP2 | |
| SCHEMBL8807231 | 0.81 | CHRM3 (0.54) | OPRD1CHRM2CHRM3LMNAALDH1A1 | |
| SCHEMBL27763113 | 0.80 | OPRD1 (0.53) | OPRD1CHRM2CHRM3LMNAALDH1A1 | |
| SCHEMBL3931511 | 0.77 | MEN1 (0.41) | OPRD1ALDH1A1MAPK1CYP3A4TDP1 | |
| Hydrochloric Acid SCHEMBL31108133 | 0.77 | CHRM2 (0.54) | OPRD1CHRM2CHRM3LMNAALDH1A1 | |
| SCHEMBL8920546 | 0.75 | LMNA (0.55) | OPRD1CHRM2CHRM3LMNAALDH1A1 | |
| SCHEMBL13681469 | 0.75 | OPRD1 (0.49) | OPRD1CHRM2CHRM3LMNAALDH1A1 | |
| SCHEMBL25896109 | 0.74 | CHRM1 (0.48) | CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303138-A1 | Combination Therapy Of Substituted Oxazolidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-10-20 | — | — | US | disclosed |
| US-20150166568-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-18 | — | — | US | disclosed |
| US-8822458-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| EP-1526132-B1 | Substituted oxazolidinone derivatives and their use as factor xa inhibitors | BAYER IP GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-20130316999-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-28 | — | — | US | disclosed |
| US-8530505-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-10 | — | — | US | disclosed |
| US-20130005701-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-01-03 | — | — | US | disclosed |
| CN-1900074-B | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER SCHERING PHARMA AG | 2012-07-11 | — | — | CN | disclosed |
| US-8129378-B2 | Rivaroxaban and derivatives, synthesis; atherosclerosis; arthritis; Alzheimer's disease or cancer | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20100267685-A1 | Methods For The Prophylaxis And/or Treatment Of Thromboembolic Disorders By Combination Therapy With Substituted Oxazolidinones | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-21 | — | — | US | disclosed |
| EP-1526132-A2 | Substituted oxazolidinone derivatives and their use as factor xa inhibitors | Bayer HealthCare AG (DE) | 2005-04-27 | — | — | EP | disclosed |
| EP-1261606-B1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER HEALTHCARE AG (DE) | 2005-02-23 | — | — | EP | disclosed |
| US-20040242660-A1 | Combinations of oxazolidinones with other active ingredients for the prophylaxis and/or treatment of thromboembolic disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
| EP-1411932-A1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | Bayer HealthCare AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030153610-A1 | Substituted oxazolidinones and their in the field of blood coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2003-08-14 | — | — | US | disclosed |
| CN-1434822-A | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER AG (DE) | 2003-08-06 | — | — | CN | disclosed |
| WO-2003000256-A9 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | BAYER AG (DE) | 2003-02-06 | — | — | WO | disclosed |
| WO-2003000256-A1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | BAYER HEALTHCARE AG (DE) | 2003-01-03 | — | — | WO | disclosed |
| EP-1261606-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | Bayer Aktiengesellschaft (DE) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001047919-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303138-A1 | Combination Therapy Of Substituted Oxazolidinones | P2RY12, P2RY11, P2RY1 | OPRD1 173/4885CHRM2 1378/4885CHRM3 1083/4885 |
| US-20130005701-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | OPRD1 838/4885CHRM2 4626/4885CHRM3 4470/4885 |
| US-20130316999-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | OPRD1 838/4885CHRM2 4626/4885CHRM3 4470/4885 |
| US-20040242660-A1 | Combinations of oxazolidinones with other active ingredients for the prophylaxis and/or treatment of thromboembolic disorders | SERPINC1, XDH, SDHB | OPRD1 1889/4885CHRM2 4500/4885CHRM3 4531/4885 |
| US-20100267685-A1 | Methods For The Prophylaxis And/or Treatment Of Thromboembolic Disorders By Combination Therapy With Substituted Oxazolidinones | SERPINC1, SDHB, F2 | OPRD1 2190/4885CHRM2 4517/4885CHRM3 4577/4885 |
| US-20030153610-A1 | Substituted oxazolidinones and their in the field of blood coagulation | F2, F11, SERPINC1 | OPRD1 941/4885CHRM2 4404/4885CHRM3 4487/4885 |
| US-20150166568-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | OPRD1 838/4885CHRM2 4626/4885CHRM3 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.